Companies Evommune, Inc.
Evommune (EVMN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Evommune, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $7,444,605FY2024
- $11,022,670FY2025
CEO total pay was $11,022,670 in fiscal 2025, up from $7,444,605 in fiscal 2024.
FY2025: salary $588,462 · bonus $740,675 · stock awards $0 · option awards $9,693,533
Order EVMN
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Luis Peña | $588,462 | $740,675 | $0 | $9,693,533 | $0 | $0 | $0 | $11,022,670 |
| Chief Executive Officer | ||||||||
| Gregory Moss | 515,042 | 508,433 | 0 | 3,570,591 | 0 | 0 | 6,900 | 4,600,966 |
| Chief Business & Legal Officer | ||||||||
| Kyle Carver | 501,875 | 496,658 | 0 | 3,399,210 | 0 | 0 | 6,900 | 4,404,643 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Luis Peña | $11,022,670 | $7,444,605 | — | ↑ +3,578,065 |
| Gregory Moss | 4,600,966 | 1,355,474 | — | ↑ +3,245,492 |
| Kyle Carver | 4,404,643 | 1,237,071 | — | ↑ +3,167,572 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation philosophy is designed to align named executive officers' interests with those of stockholders and to retain and incentivize them over the long-term. Base salaries are established based on role, responsibilities, and market levels, while equity-based incentive awards serve as a retention measure tied to continuous service and corporate goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kyle Carver | Option | 3,570 | 1.71 | — |
| Gregory Moss | Option | 4,214 | 1.71 | — |
| Kyle Carver | Option | 7,404 | 3.07 | — |
| Kyle Carver | Option | 8,344 | 3.58 | — |
| Gregory Moss | Option | 9,567 | 3.58 | — |
| Luis Peña | Option | 12,395 | 1.71 | — |
| Gregory Moss | Option | 16,730 | 3.07 | — |
| Kyle Carver | Option | 20,413 | 3.84 | — |
| Gregory Moss | Option | 23,134 | 3.84 | — |
| Luis Peña | Option | 27,813 | 3.58 | — |
| Gregory Moss | Option | 34,914 | 1.71 | — |
| Luis Peña | Option | 41,129 | 3.07 | — |
| Kyle Carver | RSU | 54,469 | — | 932,509 |
| Gregory Moss | RSU | 55,845 | — | 956,066 |
| Luis Peña | Option | 68,041 | 3.84 | — |
| Kyle Carver | Option | 83,799 | 2.99 | — |
| Gregory Moss | Option | 85,914 | 2.99 | — |
| Luis Peña | RSU | 141,753 | — | 2,426,811 |
| Luis Peña | Option | 218,081 | 2.99 | — |
| Kyle Carver | Option | 279,408 | 16 | — |
| Gregory Moss | Option | 293,496 | 16 | — |
| Luis Peña | Option | 444,992 | 2.99 | — |
| Luis Peña | Option | 796,841 | 16 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Benjamin F. McGraw III, Pharm.DIndependent · Board Chair · Audit · Compensation (Chair) · Nominating and Corporate Governance · Science and Technology · Not standing for re-election | $50,833 | — | $439,994 | — | — | $490,827 |
| David E. Cohen, M.D., M.P.HIndependent · Compensation · Nominating and Corporate Governance (Chair) · Science and Technology (Chair) · Not standing for re-election | 44,583 | — | 439,994 | — | — | 484,577 |
| Arthur KirschIndependent · Audit (Chair) · Compensation · Not standing for re-election | 11,250 | — | 439,994 | — | — | 451,244 |
| Eugene A. Bauer, M.DEmployee director · Science and Technology | — | — | — | — | — | 0 |
| Rob Hopfner, R.Ph., Ph.DIndependent · Audit · Science and Technology · Not standing for re-election | 0 | — | 0 | — | — | 0 |
| François Beaubien, Ph.D., C.F.AIndependent · Not standing for re-election · Departed during FY | 0 | — | 0 | — | — | 0 |
| Felice Verduyn-van WeegenIndependent · Nominating and Corporate Governance · Science and Technology · Not standing for re-election | 0 | — | 0 | — | — | 0 |
| Luis PeñaEmployee director · Nominating and Corporate Governance | — | — | — | — | — | 0 |
| Derek DiRocco, Ph.DIndependent · Science and Technology · Not standing for re-election · Newly elected | 0 | — | 0 | — | — | 0 |
| Yuexin YuIndependent · Not standing for re-election · Departed during FY | 0 | — | 0 | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $220,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $106,666 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $106,666 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Evommune as a peer
Companies that benchmark against EVMN
No companies currently name EVMN as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Evommune, Inc. | 2025 | Luis Peña | $588,462 | $0 | $9,693,533 | $0 | $11,022,670 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-02 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (17 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Luis Peña. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 11,022,670. View filing ↗
- Section 01, Gregory Moss. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 4,600,966. View filing ↗
- Section 01, Kyle Carver. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 4,404,643. View filing ↗
- Section 08, Benjamin F. McGraw III, Pharm.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 490,827. View filing ↗
- Section 08, David E. Cohen, M.D., M.P.H. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 484,577. View filing ↗
- Section 08, Arthur Kirsch. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 451,244. View filing ↗
- Section 08, Eugene A. Bauer, M.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Rob Hopfner, R.Ph., Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, François Beaubien, Ph.D., C.F.A. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Felice Verduyn-van Weegen. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Luis Peña. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Derek DiRocco, Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Yuexin Yu. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-02. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 106,666 + equity 0 + all other 0 = 106,666, summed across the director compensation table rows.
- Evommune, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Evommune, Inc.'s own proxy. As printed: 11,022,670. View filing ↗